“Rising Integration of PDX Models in Precision Oncology and Drug Screening”
- One prominent trend in the global Patient Derived Xenograft (PDX) market is the growing integration of PDX models into precision oncology and personalized drug screening platforms
- These models offer high fidelity in replicating human tumor heterogeneity and microenvironments, enabling more accurate assessment of treatment responses and biomarker identification
- For instance, pharmaceutical companies are increasingly using PDX platforms to screen targeted therapies and immuno-oncology drugs, improving clinical trial success rates and accelerating time-to-market for novel treatments
- This trend is significantly transforming preclinical cancer research by enhancing the predictive power of drug testing, supporting personalized treatment strategies, and driving demand for PDX-based solutions across academic and commercial R&D settings
